CO6210816A2 - Heterociclos biciclicos medicamentos que contienen estos compuestos su utilizacion y procedimientos para su preparacion - Google Patents

Heterociclos biciclicos medicamentos que contienen estos compuestos su utilizacion y procedimientos para su preparacion

Info

Publication number
CO6210816A2
CO6210816A2 CO09081877A CO09081877A CO6210816A2 CO 6210816 A2 CO6210816 A2 CO 6210816A2 CO 09081877 A CO09081877 A CO 09081877A CO 09081877 A CO09081877 A CO 09081877A CO 6210816 A2 CO6210816 A2 CO 6210816A2
Authority
CO
Colombia
Prior art keywords
alkyl
group
sulfonylamino
fluorine
amino
Prior art date
Application number
CO09081877A
Other languages
English (en)
Inventor
Frank Himmelsbach
Birgit Jung
Ralf Lotz
Markus Ostermeier
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07101785A external-priority patent/EP1956010A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CO6210816A2 publication Critical patent/CO6210816A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

1.- Heterociclos bicíclicos de la fórmula generalen los cuales Ra es un grupo fenilo, 1-feniletilo o indan-4-ilo, en los que el núcleo fenilo está sustituido en cada caso con los radicales R1 a R3, donde R1 y R2, que pueden ser iguales o diferentes, son en cada caso un átomo de hidrógeno, flúor, cloro, bromo o yodo, un grupo alquilo C1-4, hidroxi, alcoxi C1-4, alquenilo C2-3 o alquinilo C2-3, un grupo arilo, ariloxio, arilmetilo o arilmetoxi, un grupo heteroarilo, heteroariloxi, heteroarilmetilo o heteroarilmetoxi, un grupo metilo o metoxi sustituido con 1 a 3 átomos de flúor o un grupo ciano, nitro o amino, y R3 un átomo de hidrógeno, flúor, cloro o bromo o un grupo metilo o trifluorometilo, Rb un grupo azetidin-1-ilo, pirrolidin-1-ilo, piperidin-1-ilo, homiperidin-1-ilo, morfolin-4-ilo, homomorfolin-4-ilo, piperazin1-ilo, 4-(alquil C1-4-carbonil)-piperazin-1-ilo, 4-(alquil C1-4-sulfonil)-piperazin-1-ilo, homopiperazin-1-ilo, 4-(alquil C1-4-carbonil)-homopiperazin-1-ilo o 4-(alquil C1-4- sulfonil)-homopiperazin-1-ilo, que en cada caso puede estar mono-, di- o trisustituido con R4, en donde los sustituyentes pueden ser iguales o diferentes y R4 representa un átomo de flúor, cloro, bromo o yodo, un grupo alquilo C1-4, alquenilo C2-4 o alquinilo C2-4, un grupo metilo o metoxi sustituido con 1 a 3 átomos de flúor,un grupo amino, alquil C1-4-amino, di-(alquil C1-4)amino, alquil C1-4-carbonilamino, N-(alquil C1-4)-alquil C1-4-carbonilamino, alquil C1-4-sulfonilamino o N-(alquil C1-4)-alquil C1-4-sulfonilamino, un grupo amino-alquilo C1-4, alquil C1-4-amino-alquilo C1-4, di-(alquil C1-4)amino-alquilo C1-4, alquil C1-4-carbonilamino-alquilo C1-4, N-(alquil C1-4)-alquil C1-4-carbonilamino-alquilo C1-4, alquil C1-4-sulfonilamino-alquilo C1-4 o N-(alquil C1-4)-alquil C1-4-sulfonilamino-alquilo C1-4, un grupo hidroxi, alquil C1-4-oxi o alquil C1-4-carboniloxi un grupo hidroxi-alquilo C1-4, alquil C1-4-oxi-alquilo C1-4 o alquil C1-4-carboniloxi-alquilo C1-4, ...
CO09081877A 2007-02-06 2009-08-05 Heterociclos biciclicos medicamentos que contienen estos compuestos su utilizacion y procedimientos para su preparacion CO6210816A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07101785A EP1956010A1 (de) 2007-02-06 2007-02-06 Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel,deren Verwendung und Verfahren zu ihrer Herstellung
EP07118700 2007-10-17

Publications (1)

Publication Number Publication Date
CO6210816A2 true CO6210816A2 (es) 2010-10-20

Family

ID=39247377

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09081877A CO6210816A2 (es) 2007-02-06 2009-08-05 Heterociclos biciclicos medicamentos que contienen estos compuestos su utilizacion y procedimientos para su preparacion

Country Status (18)

Country Link
US (1) US7998949B2 (es)
EP (1) EP2118075A1 (es)
JP (1) JP5377332B2 (es)
KR (1) KR20090116782A (es)
AR (1) AR065195A1 (es)
AU (1) AU2008212999A1 (es)
BR (1) BRPI0807234A2 (es)
CA (1) CA2677336A1 (es)
CL (1) CL2008000356A1 (es)
CO (1) CO6210816A2 (es)
EA (1) EA200901041A1 (es)
EC (1) ECSP099562A (es)
IL (1) IL199923A0 (es)
MA (1) MA31171B1 (es)
MX (1) MX2009007610A (es)
TN (1) TN2009000332A1 (es)
TW (1) TW200846330A (es)
WO (1) WO2008095847A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1921070A1 (de) * 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
ME01461B (me) 2008-02-07 2014-04-20 Boehringer Ingelheim Int Spirociklični heterocikli, ljekovi koji sadrže navedeno jedinjenje, njihova primjena i postupak za njihovu proizvodnju.
JP5611207B2 (ja) * 2008-08-08 2014-10-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式複素環の立体選択的調製方法
EP2313397B1 (de) * 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US8629153B2 (en) 2008-09-03 2014-01-14 Boehringer Ingelheim International Gmbh Use of quinazoline derivatives for the treatment of viral diseases
EP2289881A1 (de) * 2009-08-06 2011-03-02 Boehringer Ingelheim International GmbH Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen
EA201201052A1 (ru) 2010-01-29 2013-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные нафтиридины и их применение в качестве ингибиторов киназы syk
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985749A (en) 1975-12-22 1976-10-12 Eastman Kodak Company Process for preparation of 4-aminoquinazoline
JPS5538325A (en) 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4335127A (en) 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
GB2160201B (en) 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
US4845629A (en) 1985-07-18 1989-07-04 General De Investigacion Y Desarrollo S.A. Airport surveillance systems
KR910006138B1 (ko) 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체
US4921863A (en) 1988-02-17 1990-05-01 Eisai Co., Ltd. Cyclic amine derivatives
GB8910722D0 (en) 1989-05-10 1989-06-28 Smithkline Beckman Intercredit Compounds
US5252586A (en) 1990-09-28 1993-10-12 The Du Pont Merck Pharmaceutical Company Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents
DE4105503A1 (de) 1991-02-19 1992-08-20 Jenapharm Gmbh Ausgangsverbindungen zur herstellung von calcitriol sowie dessen abkoemmlingen, verfahren zur herstellung dieser ausgangsverbindungen sowie zwischenprodukte fuer dieses verfahren
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5187168A (en) 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
WO1993017682A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
KR100322325B1 (ko) 1993-05-26 2002-06-20 헤르빅 폰 모르체 신규한1-페닐알카논5-ht4수용체리간드
US5395846A (en) 1993-06-25 1995-03-07 Rhone-Poulenc Rorer Pharmaceuticals Inc. Amino Bi- and tri-carbocyclic aklane bis-aryl squalene synthase inhibitors
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (es) 1994-11-12 1997-12-01 Zeneca Ltd
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
US5642285A (en) 1995-01-31 1997-06-24 Trimble Navigation Limited Outdoor movie camera GPS-position and time code data-logging for special effects production
EP2295415A1 (en) 1995-03-30 2011-03-16 OSI Pharmaceuticals, Inc. Quinazoline derivatives
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508535D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
EP0824525B1 (en) 1995-04-27 2001-06-13 AstraZeneca AB Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6046206A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
JPH11512708A (ja) 1995-09-11 1999-11-02 オステオアルスリィティス サイエンシズ，インコーポレイテッド 変形性関節炎を治療するためのプロテインチロシンキナーゼインヒビター
WO1997018813A1 (en) 1995-11-22 1997-05-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9702049B1 (pt) 1996-01-31 2010-08-10 sistema distribuidor contendo dois compartimentos para a dosagem simultánea de duas composições aquosas.
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
TR199801530T2 (xx) 1996-02-13 1998-11-23 Zeneca Limited VEGF �nhibit�rleri olarak kinazolin t�revleri.
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド ４―アニリノキナゾリン誘導体
PL190489B1 (pl) 1996-04-12 2005-12-30 Warner Lambert Co Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
US5938706A (en) 1996-07-08 1999-08-17 Feldman; Yasha I. Multi element security system
ES2186908T3 (es) 1996-07-13 2003-05-16 Glaxo Group Ltd Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas.
US6004967A (en) 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
DE69740095D1 (de) 1996-11-05 2011-02-17 Childrens Medical Center Thalidomide und Dexamethason für die Behandlung von Tumors
ATE554750T1 (de) 1997-03-05 2012-05-15 Sugen Inc Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US5929080A (en) 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
WO1998050038A1 (en) 1997-05-06 1998-11-12 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
ATE260931T1 (de) 1997-06-30 2004-03-15 Glaxo Group Ltd Verfahren zur identifizierung von verbindungen mit verminderter systemischer aktivität
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
ATE368665T1 (de) 1997-08-22 2007-08-15 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
KR20010031813A (ko) 1997-11-06 2001-04-16 윌리암 에이취 캘넌, 에곤 이 버그 결장 폴립 치료용 티로신 키나제 억제제로서의 퀴나졸린유도체의 용도
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
AU4317399A (en) 1998-05-28 1999-12-13 Parker Hughes Institute Quinazolines for treating brain tumor
AU4851599A (en) 1998-06-30 2000-01-17 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
AR020114A1 (es) 1998-07-30 2002-04-10 America Home Products Corp Proceso para la preparacion de derivados de quinazolina sustituida y compuestos para su exclusivo uso en dicho proceso
US6384223B1 (en) 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
WO2000009481A1 (fr) 1998-08-11 2000-02-24 Takeda Chemical Industries, Ltd. Composes d'amide cyclique, procedes de production correspondants, intermediaires correspondants et herbicides
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
BR9912672A (pt) 1998-08-18 2002-06-11 Univ California Prevenção de produção de muco no trato respiratório por administração de antagonistas de egf-r
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
WO2000010981A1 (en) 1998-08-21 2000-03-02 Parker Hughes Institute Quinazoline derivatives
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
CN1144786C (zh) 1998-09-29 2004-04-07 美国氰胺公司 作为蛋白质酪氨酸激酶抑制剂的取代的3-氰基喹啉
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
IL142257A0 (en) 1998-10-01 2002-03-10 Astrazeneca Ab Amide derivatives, process for their preparation, compositions containing them and use thereof in the manufacture of a medicament for the treatment of cytokine-mediated diseases
TW575567B (en) 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
CZ306810B6 (cs) 1999-02-10 2017-07-19 Astrazeneca Ab Použití chinazolinového derivátu jako inhibitoru angiogeneze
ID29800A (id) 1999-02-27 2001-10-11 Boehringer Ingelheim Pharma Turunan-turunan 4-amino-kinazolin dan kinolin yang mempunyai efek inhibitor pada transduksi signal yang dimediasi oleh tirosin kinase
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
DE19911510A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
JP2002539262A (ja) 1999-03-19 2002-11-19 パーカー ヒューズ インスティテュート キナゾリン化合物製剤および治療におけるその使用
CA2373073A1 (en) 1999-05-07 2000-11-16 Takeda Chemical Industries, Ltd. Cyclic compounds and uses thereof
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6126917A (en) 1999-06-01 2000-10-03 Hadasit Medical Research Services And Development Ltd. Epidermal growth factor receptor binding compounds for positron emission tomography
YU90901A (sh) 1999-06-21 2004-07-15 Boehringer Ingelheim Pharma Gmbh. & Co.Kg. Biciklični heterocikli, lekovi koji sadrže ta jedinjenja, njihova primena i postupci za njihovo pripremanje
WO2001004102A1 (en) 1999-07-07 2001-01-18 Astrazeneca Uk Limited Quinazoline derivatives
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
IL147913A0 (en) 1999-08-12 2002-08-14 American Cyanamid Co Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
AU763242B2 (en) 1999-09-21 2003-07-17 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
RU2002110461A (ru) 1999-09-21 2004-03-10 Астразенека Аб (Se) Производные хиназолина и их применение в качестве фармацевтических веществ
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
GB9922173D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
SV2002000205A (es) 1999-11-01 2002-06-07 Lilly Co Eli Compuestos farmaceuticos ref. x-01095
UA72946C2 (uk) 1999-11-05 2005-05-16 Астразенека Аб Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
JP2003518023A (ja) 1999-11-30 2003-06-03 パーカー ヒューズ インスティテュート トロンビン誘導血小板凝集の阻害剤
DE60112268T2 (de) 2000-03-06 2006-05-24 Astrazeneca Ab Verwendung von quinazolinderivate als inhibitoren der angiogenese
US20060063752A1 (en) 2000-03-14 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
JP4970689B2 (ja) 2000-04-07 2012-07-11 アストラゼネカ アクチボラグ キナゾリン化合物
MXPA02009855A (es) 2000-04-08 2003-03-27 Boehringer Ingelheim Pharma Heterociclos biciclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion.
US6627634B2 (en) 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
WO2001087293A1 (fr) 2000-05-19 2001-11-22 Takeda Chemical Industries, Ltd. Inhibiteurs de la ?-secretase
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
CA2413424C (en) 2000-06-22 2007-10-02 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth
CZ2003486A3 (cs) 2000-08-21 2003-05-14 Astrazeneca Ab Chinazolinové deriváty, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6656946B2 (en) 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6653305B2 (en) 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
US6403580B1 (en) 2000-08-26 2002-06-11 Boehringer Ingelheim Pharma Kg Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE10042059A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6617329B2 (en) 2000-08-26 2003-09-09 Boehringer Ingelheim Pharma Kg Aminoquinazolines and their use as medicaments
US20020082270A1 (en) 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042061A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042062A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Hertellung
DE10042060A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6740651B2 (en) 2000-08-26 2004-05-25 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
AU2002218192A1 (en) 2000-09-21 2002-04-02 Smithkline Beecham Plc Quinoline derivatives as antibacterials
JP2004511479A (ja) 2000-10-13 2004-04-15 アストラゼネカ　アクチボラグ キナゾリン誘導体
MXPA03009130A (es) 2000-10-20 2004-02-26 Biocryst Pharm Inc Compuestos de biarilo que funcionan como inhibidores de proteasa serina.
WO2002034744A1 (en) 2000-10-25 2002-05-02 Astrazeneca Ab Quinazoline derivatives
US20030158196A1 (en) 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US7067532B2 (en) 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents
ATE369894T1 (de) 2000-11-22 2007-09-15 Novartis Pharma Gmbh Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
WO2002062767A1 (fr) 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Nouveaux derives de quinazoline
NZ516873A (en) 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
DE60237145D1 (de) 2001-02-21 2010-09-09 Mitsubishi Tanabe Pharma Corp Chinazolinderivate
PL364625A1 (en) 2001-02-23 2004-12-13 Merck & Co, Inc. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
US6562319B2 (en) 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
AR035791A1 (es) 2001-03-23 2004-07-14 Bayer Corp Compuesto n,n-diheterociclico de amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y proceso para la preparacion del compuesto
JP4615755B2 (ja) 2001-04-04 2011-01-19 セイコーインスツル株式会社 半導体装置の製造方法
WO2002092577A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
WO2002092579A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab 4-anilinoquinazoline derivatives
WO2002092578A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
AR033765A1 (es) 2001-05-22 2004-01-07 Syngenta Participations Ag Procedimiento para la preparacion de derivados 3-alquil-3h-isobenzofuran-1-ona 7-sustituidos.
WO2002094790A1 (fr) 2001-05-23 2002-11-28 Mitsubishi Pharma Corporation Compose heterocyclique condense et son utilisation medicale
AU2002350105A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
EP1444210B1 (en) 2001-11-03 2009-02-18 AstraZeneca AB Qunazoline derivatives as antitumor agents
GB0128108D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
GB0128109D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
CN1602195A (zh) 2001-12-12 2005-03-30 辉瑞产品公司 用于治疗异常细胞生长的喹唑啉衍生物
DE10204462A1 (de) 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
TW200813014A (en) 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EA200701302A1 (ru) * 2002-03-30 2007-12-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг 4-(n-фениламино)хиназолины/-хинолины в качестве ингибиторов тирозинкиназы
US20040044014A1 (en) 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
KR20050122199A (ko) 2003-01-23 2005-12-28 티.케이. 시그널 리미티드 표피성장인자 수용체 티로신 키나제의 비가역성 억제제 및 그의 용도
GB0309009D0 (en) 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
DE10326186A1 (de) 2003-06-06 2004-12-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US20050059661A1 (en) 2003-07-28 2005-03-17 Boehringer Ingelheim International Gmbh Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
CA2533345A1 (en) 2003-07-29 2005-02-10 Astrazeneca Ab Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
GB0321648D0 (en) 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
CN1882573A (zh) 2003-09-16 2006-12-20 阿斯利康(瑞典)有限公司 作为酪氨酸激酶抑制剂的喹唑啉衍生物
US20070037837A1 (en) 2003-09-19 2007-02-15 Hennequin Laurent Francois A Quinazoline derivatives
SI1667992T1 (sl) 2003-09-19 2007-06-30 Astrazeneca Ab Kinazolinski derivati
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
MXPA06003341A (es) 2003-09-25 2006-06-08 Astrazeneca Ab Derivados de quinazolina.
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10350717A1 (de) 2003-10-30 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
EP1817310A1 (en) 2004-09-17 2007-08-15 OSI Pharmaceuticals, Inc. (spirocyclylamido) aminothiophene compounds as c-kit proto-oncogene inhibitors
EP1966189A1 (de) 2005-12-12 2008-09-10 Boehringer Ingelheim International Gmbh Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung

Also Published As

Publication number Publication date
JP2010518045A (ja) 2010-05-27
EP2118075A1 (de) 2009-11-18
AU2008212999A1 (en) 2008-08-14
US7998949B2 (en) 2011-08-16
US20100022505A1 (en) 2010-01-28
EA200901041A1 (ru) 2010-02-26
KR20090116782A (ko) 2009-11-11
TW200846330A (en) 2008-12-01
JP5377332B2 (ja) 2013-12-25
CA2677336A1 (en) 2008-08-14
CL2008000356A1 (es) 2009-03-27
AR065195A1 (es) 2009-05-20
IL199923A0 (en) 2010-04-15
WO2008095847A1 (de) 2008-08-14
BRPI0807234A2 (pt) 2014-06-03
MA31171B1 (fr) 2010-02-01
TN2009000332A1 (fr) 2010-12-31
MX2009007610A (es) 2009-07-24
ECSP099562A (es) 2009-09-29

Similar Documents

Publication Publication Date Title
CO6210816A2 (es) Heterociclos biciclicos medicamentos que contienen estos compuestos su utilizacion y procedimientos para su preparacion
CO6290657A2 (es) Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica
ES2524966T3 (es) Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer
UY32997A (es) Derivados bencimidazol-imidazol
AR083676A1 (es) Compuestos heterociclicos, útiles como inhibidores de quinasa y composiciones farmaceuticas que los contienen
AR098912A1 (es) Inhibidores de syk
ECSP099781A (es) Novedosos compuestos que son inhibidores de erk
CU23834B1 (es) Compuestos de pirazolo [3,4-d] pirimidinona y sus derivados para la inhibición pde9
AR098048A1 (es) Inhibidores de fgfr4
ECSP10010415A (es) Compuestos novedosos que son inhibidores de erk
ES2563320T3 (es) Tintes azoicos dispersos
AR044799A1 (es) Derivados de amidas, composiciones farmaceuticas. su uso en el metabolismo de los lipidos.
AR067058A1 (es) Oxazolidinonas sustituidas y su uso para preparar medicamentos
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
CO6362013A2 (es) Derivados de rifamicina
AR070648A1 (es) Derivados de bencimidazol sustituido
AR105928A1 (es) Compuesto para usar composiciones que cambian de color
PE20160934A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolisis
CU23761B7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CU20090064A7 (es) Nuevos derivados de benzamida como antagonistas de la bradiquinina
AR103742A1 (es) Derivados de trifluorometilpropanamida
RS54567B1 (en) 1H-INDASOL-3-CARBOXAMIDE COMPOUNDS AS INHIBITORS OF 3-BETA KINASE GLYCOGEN SYNTHETASE
AR077140A1 (es) Derivados de pirazina como inhibidores de dgat-1, un proceso para prepararlos y una composicion farmaceutica que los comprende
AR087893A1 (es) Composiciones y metodos para el tratamiento de formaciones subterraneas de elevada temperatura
RS54487B1 (en) 2-OXO-1-IMIDAZOLIDINIL DERIVATIVES IMIDAZOTIADIAZOL

Legal Events

Date Code Title Description
FC Application refused